EXELIXIS, INC.
EXELAPI behind this page
EXEL FY 2025 request
Playground key active
/api/financials?ticker=EXEL&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 2,320,126 | 2,168,701 | +7.0% |
Show Product Lines breakouts |
|||
| CABOMETYX | 2,113,369 | 1,798,237 | +17.5% |
| Collaboration services revenues | 197,322 | 359,306 | -45.1% |
| COMETRIQ | 9,435 | 11,158 | -15.4% |
| Discounts and allowances | -889,003 | -708,851 | -25.4% |
| Gross product revenues | 3,011,807 | 2,518,246 | +19.6% |
| License | 214,375 | 349,244 | -38.6% |
| License · Collaborative Arrangement with Ipsen | 170,270 | 317,026 | -46.3% |
| License · Collaborative arrangement with Takeda | 20,125 | 12,915 | +55.8% |
| Product | 2,122,804 | 1,809,395 | +17.3% |
| Service | -17,053 | 10,062 | -269.5% |
| Service · Collaborative Arrangement with Ipsen | -16,105 | 1,607 | -1102.2% |
| Service · Collaborative arrangement with Takeda | -948 | 8,455 | -111.2% |
Show Business Segments breakouts |
|||
| Reportable Segment | 2,320,126 | 2,168,701 | +7.0% |
Show Geography breakouts |
|||
| Europe | 154,165 | 318,633 | -51.6% |
| JP | 25,590 | 27,076 | -5.5% |
| US | 2,140,371 | 1,822,992 | +17.4% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement with Ipsen | 154,165 | 318,633 | -51.6% |
| Collaborative arrangement with Takeda | 19,177 | 21,370 | -10.3% |
| Cost of Revenue | 83,697 | 76,216 | +9.8% |
Show Business Segments breakouts |
|||
| Reportable Segment | 83,697 | 76,216 | +9.8% |
| Research & Development | 825,001 | 910,408 | -9.4% |
Show Type Of Arrangement breakouts |
|||
| Research Collaborations, In-Licensing Arrangements and Other Business Development Activities | 25.7 | 69.2 | -62.9% |
| Selling, General & Administrative | 518,727 | 492,128 | +5.4% |
| Restructuring Charges | 20,510 | 33,660 | -39.1% |
| Total Costs & Expenses | 1,447,935 | 1,564,084 | -7.4% |
| Operating Income | 872,191 | 604,617 | +44.3% |
| Interest Income Other | 69,213 | 77,156 | -10.3% |
Show Business Segments breakouts |
|||
| Reportable Segment | 69,213 | 77,156 | -10.3% |
| Other Non-Operating Income (Expense) | -198 | -133 | -48.9% |
| Income Loss Attributable To Parent | 941,206 | 681,640 | +38.1% |
| Income Tax Expense (Benefit) | 158,636 | 160,373 | -1.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | 158,636 | 160,373 | -1.1% |
| Net Income | 782,570 | 521,267 | +50.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | 782,570 | 521,267 | +50.1% |
Show Equity Components breakouts |
|||
| Retained Earnings | 782,570 | 521,267 | +50.1% |
| EPS (Basic) | 2.88 | 1.8 | +60.0% |
| EPS (Diluted) | 2.78 | 1.76 | +58.0% |
| Wtd Avg Shares (Basic) | 271,567 | 290,030 | -6.4% |
| Wtd Avg Shares (Diluted) | 281,863 | 296,132 | -4.8% |
| Comprehensive Income | 787,393 | 523,670 | +50.4% |
| Other Comprehensive Income | 4,823 | 2,403 | +100.7% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 4,823 | 2,403 | +100.7% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 482,488 | 217,374 | +122.0% |
| Marketable Securities (Current) | 576,603 | 893,902 | -35.5% |
| Receivables Net Current | 286,916 | 265,437 | +8.1% |
| Inventory | 21,686 | 22,388 | -3.1% |
| Prepaid Expenses & Other Current Assets | 75,596 | 68,478 | +10.4% |
| Total Current Assets | 1,443,289 | 1,467,579 | -1.7% |
| Non-Current Assets | |||
| Marketable Securities (Non-Current) | 603,603 | 637,291 | -5.3% |
| Property, Plant & Equipment | 98,960 | 119,391 | -17.1% |
| Deferred Tax Assets | 292,582 | 420,027 | -30.3% |
| Goodwill | 63,684 | 63,684 | 0.0% |
| Total Assets | 2,844,423 | 2,947,690 | -3.5% |
| Operating Lease Right-of-Use Assets | 159,036 | 172,564 | -7.8% |
| Other Assets | |||
| Operating Lease Right Of Use Asset And Other Non Current Assets | 342,305 | 239,718 | +42.8% |
| Current Liabilities | |||
| Accounts Payable | 29,623 | 38,191 | -22.4% |
| Accrued Employee Benefits Current | 102,218 | 109,830 | -6.9% |
| Accrued Clinical Liabilities Current | 65,742 | 57,976 | +13.4% |
| Customer Refund Liability Current | 59,896 | 62,376 | -4.0% |
| Accrued Collaboration Liability Current | 22,783 | 40,384 | -43.6% |
| Other Liabilities Current | 125,382 | 95,012 | +32.0% |
Show Product Lines breakouts |
|||
| Branded Prescription Drug fee | 27.7 | 26.2 | +5.7% |
| Total Current Liabilities | 405,644 | 403,769 | +0.5% |
| Deferred Revenue (Current) | 1,115 | 2,739 | -59.3% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 173,038 | 190,823 | -9.3% |
| Other Non-Current Liabilities | 104,422 | 108,895 | -4.1% |
| Total Liabilities | 683,104 | 703,487 | -2.9% |
| Contract With Customer Liability Noncurrent | 6,112 | 3,392 | +80.2% |
| Stockholders' Equity | |||
| Common Stock | 262 | 282 | -7.1% |
| Additional Paid-In Capital | 2,234,411 | 2,343,915 | -4.7% |
| Accumulated Other Comprehensive Income | 3,476 | -1,347 | +358.1% |
| Retained Earnings | -76,830 | -98,647 | +22.1% |
| Total Stockholders' Equity | 2,161,319 | 2,244,203 | -3.7% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 3,476 | -1,347 | +358.1% |
| Additional Paid In Capital | 2,234,411 | 2,343,915 | -4.7% |
| Common Stock | 262 | 282 | -7.1% |
| Retained Earnings | -76,830 | -98,647 | +22.1% |
| Total Liabilities & Equity | 2,844,423 | 2,947,690 | -3.5% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 29,055 | 28,803 | +0.9% |
| Stock-Based Compensation | 112,983 | 93,836 | +20.4% |
| Noncash Lease Expense | 24,229 | 27,461 | -11.8% |
| Increase Decrease In Deferred Income Taxes | 126,237 | -59,458 | +312.3% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 11,999 | 50,750 | -76.4% |
| Other Non-Cash Items | -11,609 | -13,626 | +14.8% |
| Change in Accounts Receivable | -21,398 | -27,950 | +23.4% |
| Change in Inventory | 12,225 | 5,453 | +124.2% |
| Change in Prepaid & Other Assets | -133,771 | 31,079 | -530.4% |
| Increase Decrease In Accrued Liabilities | 1,899 | -149 | +1374.5% |
| Change in Accounts Payable | -50,152 | -21,886 | -129.2% |
| Net Cash from Operations | 884,267 | 699,971 | +26.3% |
| Deferred Income Taxes | 126,237 | -59,458 | +312.3% |
| Investing Activities | |||
| Payments To Acquire Marketable Securities | -632,497 | -927,905 | +31.8% |
| Proceeds From Sale And Maturity Of Marketable Securities | 1,022,866 | 877,307 | +16.6% |
| Capital Expenditures | -8,429 | -28,435 | +70.4% |
| Payments To Acquire In Process Research And Development | -31,499 | -37,750 | +16.6% |
| Net Cash from Investing | 350,441 | -116,783 | +400.1% |
| Financing Activities | |||
| Share Repurchases | -947,511 | -652,033 | -45.3% |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 49,137 | 61,850 | -20.6% |
| Tax Withholding for Share Compensation | -71,220 | -38,625 | -84.4% |
| Net Cash from Financing | -969,594 | -628,808 | -54.2% |
| Supplemental | |||
| Income Taxes Paid | 155,296 | 170,482 | -8.9% |
| Investments Purchases Incurred But Not Yet Paid | 21,825 | — | — |
| Other Cash Flow | |||
| Net Change in Cash | 265,114 | -45,620 | +681.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 482,488 | 217,374 | +122.0% |
Values in thousands USD. Source: SEC EDGAR 10-K filing.